Breaking News, Collaborations & Alliances

Carisma, Moderna Expand CAR-M Collaboration for Autoimmune Diseases

Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, is expanding its in vivo chimeric antigen receptor macrophage and monocyte (CAR-M) collaboration with Moderna Inc. to include the nomination of two targets for the treatment of autoimmune diseases. Carisma retains all rights in autoimmune disease beyond the two nominated targets, which will be exclusively partnered with Moderna.   Under this expanded collabora...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters